Friday, Nov. 13, 2015, 93 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $24.16 to $3,621,256.80.

Highlighted Stocks Traded by Insiders:

GenMark Diagnostics (GNMK) - FREE Research Report

Chakravarty Ingo, who is SVP, International at GenMark Diagnostics, sold 591 shares at $7.17 on Nov. 13, 2015. Following this transaction, the SVP, International owned 60,738 shares meaning that the stake was reduced by 0.96% with the 591-share transaction.

The shares most recently traded at $7.30, up $0.13, or 1.78% since the insider transaction. Historical insider transactions for GenMark Diagnostics go as follows:

  • 4-Week # shares bought: 13,500
  • 4-Week # shares sold: 14,245
  • 12-Week # shares bought: 13,500
  • 12-Week # shares sold: 46,215
  • 24-Week # shares bought: 13,500
  • 24-Week # shares sold: 60,014

The average volume for GenMark Diagnostics has been 358,800 shares per day over the past 30 days. GenMark Diagnostics has a market cap of $303.0 million and is part of the health care sector and health services industry. Shares are down 47.39% year-to-date as of the close of trading on Friday.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. Currently, there are 5 analysts who rate GenMark Diagnostics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNMK - FREE

TheStreet Quant Ratings

rates GenMark Diagnostics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, deteriorating net income, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

GenMark Diagnostics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Fabrinet (FN) - FREE Research Report

Gill Harpal, who is President & COO at Fabrinet, sold 15,810 shares at $23.09 on Nov. 13, 2015. Following this transaction, the President & COO owned 192,801 shares meaning that the stake was reduced by 7.58% with the 15,810-share transaction.

Olson Rollance E., who is Director at Fabrinet, sold 5,000 shares at $23.02 on Nov. 13, 2015. Following this transaction, the Director owned 44,668 shares meaning that the stake was reduced by 10.07% with the 5,000-share transaction.

Ng Toh-Seng, who is Chief Financial Officer at Fabrinet, sold 2,655 shares at $23.26 on Nov. 13, 2015. Following this transaction, the Chief Financial Officer owned 122,258 shares meaning that the stake was reduced by 2.13% with the 2,655-share transaction.

The shares most recently traded at $23.29, up $0.03, or 0.13% since the insider transaction. Historical insider transactions for Fabrinet go as follows:

  • 4-Week # shares sold: 85,184
  • 12-Week # shares sold: 112,662
  • 24-Week # shares sold: 112,662

The average volume for Fabrinet has been 287,500 shares per day over the past 30 days. Fabrinet has a market cap of $832.3 million and is part of the consumer goods sector and consumer durables industry. Shares are up 31.12% year-to-date as of the close of trading on Friday.

Fabrinet provides optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of optical communication components, modules and sub-systems, industrial lasers, medical devices, and sensors. The company has a P/E ratio of 24.7. Currently, there are 6 analysts who rate Fabrinet a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FN - FREE

TheStreet Quant Ratings

rates Fabrinet as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Fabrinet Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Salesforce.com (CRM) - FREE Research Report

Benioff Marc, who is Chairman of the Board & CEO at Salesforce.com, sold 25,000 shares at $77.55 on Nov. 13, 2015. Following this transaction, the Chairman of the Board & CEO owned 37.3 million shares meaning that the stake was reduced by 0.07% with the 25,000-share transaction.

The shares most recently traded at $74.90, down $2.65, or 3.54% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 229,863
  • 12-Week # shares sold: 338,472
  • 24-Week # shares sold: 346,521

The average volume for Salesforce.com has been 4.0 million shares per day over the past 30 days. Salesforce.com has a market cap of $51.7 billion and is part of the technology sector and computer software & services industry. Shares are up 27.47% year-to-date as of the close of trading on Friday.

salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship management to various businesses and industries worldwide. Currently, there are 27 analysts who rate Salesforce.com a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRM - FREE

TheStreet Quant Ratings

rates Salesforce.com as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Salesforce.com Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.